Description

Carperitide acetate is a synthetic analog of human (and porcine) atrial natriuretic peptide (ANP, aa 1–28) that binds to the NPR-A receptor. It activates cGMP-mediated pathways to induce vasodilation, promote natriuresis/diuresis, and suppress endothelin-1 secretion in a dose-dependent manner. Carperitide also antagonizes the renin-angiotensin-aldosterone system (RAAS), contributing to antifibrotic and cardioprotective effects—making it a versatile tool for researching heart failure, hypertension, and renal function.

Manufactured under GMP conditions and with 99.78% purity, this peptide ensures high experimental consistency for cardiovascular and renal models

Product Specifications

Mechanism of Action & Research Applications

Carperitide acetate activates the natriuretic peptide receptor A (NPR-A), elevating cGMP levels to:

• Promote vasodilation and reduce preload/afterload

• Stimulate natriuresis and diuresis

• Inhibit endothelin-1 secretion, reducing vasoconstriction and fibrosis

• Counteract RAAS activity, supporting cardiovascular stability
  Researchers use it in studies on heart failure, hypertension, renal dysfunction, cardiac remodeling, and vascular fibrosis.

Side Effects (For Research Context Only)

In experimental models, Carperitide acetate may produce:

• Significant reductions in blood pressure (hypotension)

• Diuretic effect with altered electrolyte balance

• In ischemia models, it may limit infarct size and improve coronary blood flow via NO-dependent mechanisms
  

Disclaimer

Carperitide Acetate is for research use only. It is not approved for any clinical, diagnostic, or therapeutic applications.